AKT1 and neoplasm: Aprepitant prevents the SP-dependent phosphorylation of ERK1/2 and Akt [65], blocks the Akt/p53 pathway [106] and inhibits tumor cell migration and angiogenesis by blocking the overexpression of matrix metalloproteinases 2 and 9, vascular endothelial growth factor receptor 1 and vascular endothelial growth factor A by tumor cells (Table 2) [56].